title: Outpatient treatment of pulmonary embolism with dalteparin.
abstract: BACKGROUND
  Pulmonary embolism is a common complication of deep vein thrombosis. It has been established that low molecular weight heparin may be used to treat deep vein thrombosis or pulmonary embolism and randomized studies have established that outpatient management of deep vein thrombosis with low molecular weight heparin is at least as effective as in-hospital management with unfractionated heparin.
  
  
  METHODS
  This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months. Outpatients included those managed exclusively out of hospital and those managed initially for 1-3 days as inpatients who then completed therapy out of hospital. Reasons for admission included hemodynamic instability; hypoxia requiring oxygen therapy; admission for another medical reason; severe pain requiring parenteral analgesia or high risk of major bleeding. Patients were followed for three months for clinically apparent recurrent venous thromboembolism and bleeding.
  
  
  RESULTS
  Between three teaching hospitals, a total of 158 patients with pulmonary embolism were identified. Fifty patients were managed as inpatients and 108 as outpatients. Of the outpatients, 27 were managed for an average of 2.5 days as inpatients and then completed dalteparin therapy as outpatients. The remaining 81 patients were managed exclusively as outpatients with dalteparin. For all outpatients the overall symptomatic recurrence rate of venous thromboembolism was 5.6% (6/108) with only 1.9% (2/108) major bleeds. There were a total of four deaths with none due to pulmonary embolism or major bleed.
  
  
  CONCLUSIONS
  This prospective study suggests that outpatient management of pulmonary embolism is feasible and safe for the majority of patients.
authors.affiliation: London Health Sciences Centre, University of Western Ontario, Canada. michael.kovacs@lhsc.on.ca
authors.forename: M J
authors.initials: MJ
authors.lastname: Kovacs
authors.forename: D
authors.initials: D
authors.lastname: Anderson
authors.forename: B
authors.initials: B
authors.lastname: Morrow
authors.forename: L
authors.initials: L
authors.lastname: Gray
authors.forename: D
authors.initials: D
authors.lastname: Touchie
authors.forename: P S
authors.initials: PS
authors.lastname: Wells
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000379:methods / Q000592:standards*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006470:Hemorrhage / Q000209:etiology; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000188:drug therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D020246:Venous Thrombosis
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017985:Dalteparin